Utilizing pooled hazard ratios (HRs) and addressing high heterogeneity (I2 = 99%), the analysis revealed a 47% reduction in AD risk (HR = 0.53) among PDE5 inhibitor users. Here, PDE5A is linked to Alzheimer disease.